Pharmacy provision of medical abortifacients in a Latin American city
Pharmacy provision of medical abortifacients in a Latin American city
复制标题
DOI：
10.1016/j.contraception.2006.05.068
复制
发表时间：
2006-11-01
期刊：
影响因子：
2.9
通讯作者：
Diaz-Olavarrieta, Claudia
中科院分区：
文献类型：
--
作者：
Lara, Diana;Abuabara, Katrina;Diaz-Olavarrieta, Claudia
目的：在拉丁美洲，获得法律的堕胎服务受到限制。尽管如此，以前的研究表明，妇女经常使用米索前列醇自我诱导堕胎。在许多情况下，妇女从药房获得药物。进行这项研究，以更好地了解药房工作人员的知识和提供的米索前列醇和其他医疗abortifacients.Methods的做法：我们首先采访了工作人员在一个随机抽样的102个药店在拉丁美洲城市。神秘客户随后被送往同一药房，以确定处方的做法和counseling.Results：近一半的药房工作人员接受采访时报告说，他们熟悉至少一个堕胎药，堕胎药被推荐在74%的神秘客户的遭遇。在调查（67%）和神秘客户（71%）中，激素注射最常被推荐为堕胎药，其次是米索前列醇（60%和39%）。很少有药房工作人员（6%的调查和17%的神秘客户遇到）建议米索前列醇剂量方案，是潜在的effective.Conclusion：Abortifacient提供是常见的药房，但有关药物的知识是低药房工作人员（c）2006年爱思唯尔公司。All rights reserved.
Purpose: Access to legal abortion services is restricted in Latin America. Nonetheless, previous research suggest that women frequently use misoprostol to self-induce abortion. In many settings, women obtain the medication from a pharmacy. This study was conducted to better understand pharmacy staff knowledge and provision practices of misoprostol and other medical abortifacients.Methods: We first interviewed staff at a random sample of 102 pharmacies in a Latin American city. Mystery clients were subsequently sent to the same pharmacies to ascertain prescribing practices and counseling.Results: Nearly half of the pharmacy staff interviewed reported that they were familiar with at least one abortifacient, and an abortifacient was recommended in 74% of the mystery client encounters. Hormonal injections were most frequently recommended as abortifacients in the survey (67%) and the mystery client encounters (71%), followed by misoprostol (60% and 39%, respectively). Few of the pharmacy staff (6% in the survey and 17% in the mystery client encounters) recommended a misoprostol dosing regimen that is potentially effective.Conclusion: Abortifacient provision is common at pharmacies but knowledge about medications is low among pharmacy staff (c) 2006 Elsevier Inc. All rights reserved.